A federal jury in Illinois awarded an Oregon man $3.2 million in a retrial of a “low testosterone” case that originally netted $150 million.
Monday’s verdict includes $200,000 in compensatory damages and $3 million in punitive damages. The verdict is the fourth in federal court involving a low testosterone gel sold by Abbott Laboratories and AbbVie Inc. that plaintiffs claim has caused heart attacks and blood clots. Plaintiffs won another $140 million verdict last year, while Abbott and AbbVie won a defense verdict in January.
